37 news items
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY
29 Apr 24
, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
BMY
26 Apr 24
', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
of care for decades but the durability of response to chemotherapy alone is poor and once a patient progresses, treatment options become increasingly
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
response
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
AGEN
BMY
12 Apr 24
response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024.
The median duration
mk7led2
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
pee0hykc26i2dsc87a1iqeyzuzb1mka827p9ukwu1sybfl6uy7hep1t1h4mc
BMY
8 Apr 24
.
With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median
ii3md3bm6 szppqmvn414zj1lfo1a4ya7dox3r7ys3en3rd2
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
t4p3gxkgi9ktundhvcbjio44xz4zeajid1a7n3aynqvfl6698a2ywd3 y3y8
BMY
IRON
VERV
4 Apr 24
with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. It is also indicated for the treatment
u7n3v865wty92bdf937vitcmctaz6gi g4vbpw1j0wuyswdb3p5gy6hyfgpc
BMY
LAB
3 Apr 24
on the development of these new tools that will accelerate insights into disease response," says Michael Egholm, President and Chief Executive Officer
7homzf
BMY
2 Apr 24
.
"In the treatment of lower-risk MDS, few patients experience a lasting response to erythroid stimulating agents, leaving a critical need for more
lvh4h38ir92bvjduy r8k
BMY
2 Apr 24
.
Established Principles for Responsible Artificial Intelligence: BMS defined and published ethical standards and practical requirements
fszuu84e6s0
BMY
ZLAB
1 Apr 24
mutation.
The study met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR
dxhaizqioohx91n0ke32j ylsw4hpda
BMY
CATX
LNTH
28 Mar 24
and Drug Administration ("FDA") based on preclinical data for the indication of SSTR2-positive NETs regardless of prior treatment response
doaf3
BMY
25 Mar 24
, monitor LVEF closely until stable doses and clinical response have been achieved
a5l6fzjuwtt4tm
BMY
20 Mar 24
in this patient population. Treatment with Abecma also showed a significant improvement in overall response